Answers are grounded in this paper and cite their sources.
We read with interest the article by Fischer et al. [1] demonstrating modulation of respiratory syncytial virus (RSV)—specific immune responses following co-administration of active pertussis toxin (PT) or an acellular diphtheria-tetanus-pertussis vaccine (DTPa) and RSV. The adjuvant and immunomodulatory properties of bacterial toxins (especially the AB toxins, such as PT, heat-labile toxin [LT] from Escherichia coli, and cholera toxin) are well recognized. We have reported that both PT [2] and LT [3] can modulate Th1 and Th2 responses to co-injected antigens. We found that active PT or a nontoxic recombinant PT molecule with mutations in the A subunit enhances Th1 and Th2 as well as IgG1 and IgG2a responses to co-injected antigens [2]. However, when we used proteins rather than formulated vaccines, we did not detect an adjuvant effect of chemically treated PT or of a PT molecule with mutations in either the S-1 or binding domains that abrogated enzyme activity and receptor interaction. In a separate study, a nontoxic mutant of LT, which retained its ability to bind to cell-surface receptors, also enhanced Th1 and Th2 responses to intranasally delivered antigens, whereas the wild-type LT selectively enhanced Th2 cells [3]. It appears that the binding and enzyme activities of certain AB toxins have distinct immunomodulatory effects on acquired immune responses, through interactions with cells of the innate immune system. The model system (live virus infection and intranasal administration of the toxin) used by Fischer et al. [1] may explain the immunomodulatory effects of PT that were different from those observed in our studies with parenterally injected purified proteins [2]. Others have reported that PT can enhance Th1, delayed-type hypersensitivity, IgG2a, Th2, IgG1, and IgE responses under different experimental conditions [4, 5]. It is well accepted that whole cell pertussis vaccines have adjuvant activity for co-injected antigens, and this has been attributed to endotoxin, which enhances interleukin (IL)—12 production [6], and also to residual levels of active PT. In contrast, adjuvant activity of the acellular pertussis vaccine, which includes chemically treated PT, has been more difficult to demonstrate. In fact, the inclusion of acellular pertussis in combination vaccines can result in reduced antibody response to other components [7], a problem that was not encountered with the whole cell pertussis vaccine. We would like to propose an additional mechanism whereby certain acellular pertussis vaccines may modify immune responses to other antigens. Most acellular pertussis vaccines include filamentous hemagglutinin (FHA), a putative protective antigen from Bordetella pertussis, and we have demonstrated that interaction of FHA with receptors on macrophages results in suppression of IL-12 production through an IL-10—dependent mechanism [8]. FHA induces the production of IL-10 and IL-6, and its potent suppression of IL-12 and interferon (IFN)—γ could be demonstrated in vivo as well as in vitro. FHA has also been shown to suppress T cell proliferation following B. pertussis infection of human monocytes [9]. These findings are consistent with suppression of IFN-γ production by antigen-specific T cells in the lung during the acute stage of infection with B. pertussis [10] and may represent a strategy for pathogen persistence by modulating the protective Th1 responses. It is also possible that FHA may affect T cell responses to unrelated antigens or pathogens. Preliminary investigations have revealed that intranasal administration of FHA suppresses virus-specific IFN-γ production in the cervical lymph nodes of mice infected with influenza virus (figure 1). Although it is not clear from the report by Fischer et al. [1] whether the Lederle Laboratories (Pearl River, NY) DTPa vaccine used included FHA, this component is present in the licensed Lederle DTPa and most of the recently developed DTPa from other manufacturers. Therefore, vaccines that include FHA as a component may have the potential to modulate immune responses to co-injected antigens, and this may explain, in part, the effect of DTPa on antibody responses to other components of combination vaccines. Although the whole cell pertussis vaccine also includes FHA, its effect is dominated by the powerful IL-12—inducing effect of residual endotoxin, which results in a highly polarized Th1 response [6]. The absence of endotoxin (which contributes to significantly improved safety), the formulation with alum, and the induction of IL-10 by FHA may also explain the induction of a Th2 or a mixed Th1/Th2 response with the DTPa. Filamentous hemagglutinin (FHA) suppresses antigen-specific interferon (IFN)—γ production in mice infected with influenza virus. BALB/c mice were infected with A/Sichuan/2/87 influenza virus (∼ 5 × 105 TCID50) by intranasal administration of virus alone or with FHA (10 µg). Control mice were given PBS. Two weeks after infection, draining lymph node cells were stimulated in vitro with inactivated influenza virus (4 or 12 µg/mL) or with medium only. IFN-γ levels were assessed by immunoassay in supernatants removed on day 3 of culture. Data represent mean (± SE) values for 4 mice per experimental group. * P < .05 vs. mice infected with influenza virus alone, by Student's t test. Regardless of the mechanism, the observation that DTPa can modulate the immune response to other components of a vaccine or to an infectious agent provides further evidence of bystander cross-regulation of Th1 and Th2 responses in vivo. These observations have important implications for the protective efficacy of vaccines during ongoing infection and for combination vaccine strategies, and they are consistent with suggestions that vaccines may modulate not only harmful immune responses to allergens or autoimmune diseases, but also beneficial immune responses to infection.
No takes yet. Share an insight, caveat, or question.
McGuirk et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: